Moderna, Inc.

Intra-Cellular Therapies, Inc.

NeoGenomics, Inc.

Corcept Therapeutics Inc.

Bruker Corporation

Halozyme Therapeutics, Inc.

Corcept Therapeutics Incorporated

Axsome Therapeutics, Inc.

Arrowhead Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.

First Trust NYSE Arca Biotechnology Index Fund

FBT (FBT) Stock Price, Analysis & Trade Signals